Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway
Osteoarthritis (OA) is the most common degenerative arthritis associated with pain and cartilage destruction in the elderly; it is known to be involved in inflammation as well. A drug called celecoxib is commonly used in patients with osteoarthritis to control pain. Metformin is used to treat type 2...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/3/681 |
id |
doaj-e5008faea95e46dc91b759f0ab4f943b |
---|---|
record_format |
Article |
spelling |
doaj-e5008faea95e46dc91b759f0ab4f943b2021-03-20T00:04:20ZengMDPI AGCells2073-44092021-03-011068168110.3390/cells10030681Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal PathwayHyun Sik Na0Ji Ye Kwon1Seon-Yeong Lee2Seung Hoon Lee3A Ram Lee4Jin Seok Woo5KyungAh Jung6Keun-Hyung Cho7Jeong-Won Choi8Dong Hwan Lee9Hong-Ki Min10Sung-Hwan Park11Seok Jung Kim12Mi-La Cho13The Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaImpact Biotech, Korea 505 Banpo-Dong, Seocho-Ku, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Orthopedic Surgery, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 11765, KoreaDivision of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul 05030, KoreaDivision of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Orthopedic Surgery, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 11765, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaOsteoarthritis (OA) is the most common degenerative arthritis associated with pain and cartilage destruction in the elderly; it is known to be involved in inflammation as well. A drug called celecoxib is commonly used in patients with osteoarthritis to control pain. Metformin is used to treat type 2 diabetes but also exhibits regulation of the autophagy pathway. The purpose of this study is to investigate whether metformin can treat monosodium iodoacetate (MIA)-induced OA in rats. Metformin was administered orally every day to rats with OA. Paw-withdrawal latency and threshold were used to assess pain severity. Cartilage damage and pain mediators in dorsal root ganglia were evaluated by histological analysis and a scoring system. Relative mRNA expression was measured by real-time PCR. Metformin reduced the progression of experimental OA and showed both antinociceptive properties and cartilage protection. The combined administration of metformin and celecoxib controlled cartilage damage more effectively than metformin alone. In chondrocytes from OA patients, metformin reduced catabolic factor gene expression and inflammatory cell death factor expression, increased LC3Ⅱb, p62, and LAMP1 expression, and induced an autophagy–lysosome fusion phenotype. We investigated if metformin treatment reduces cartilage damage and inflammatory cell death of chondrocytes. The results suggest the potential for the therapeutic use of metformin in OA patients based on its ability to suppress pain and protect cartilage.https://www.mdpi.com/2073-4409/10/3/681osteoarthritismetforminpaincartilageautophagycombination therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hyun Sik Na Ji Ye Kwon Seon-Yeong Lee Seung Hoon Lee A Ram Lee Jin Seok Woo KyungAh Jung Keun-Hyung Cho Jeong-Won Choi Dong Hwan Lee Hong-Ki Min Sung-Hwan Park Seok Jung Kim Mi-La Cho |
spellingShingle |
Hyun Sik Na Ji Ye Kwon Seon-Yeong Lee Seung Hoon Lee A Ram Lee Jin Seok Woo KyungAh Jung Keun-Hyung Cho Jeong-Won Choi Dong Hwan Lee Hong-Ki Min Sung-Hwan Park Seok Jung Kim Mi-La Cho Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway Cells osteoarthritis metformin pain cartilage autophagy combination therapy |
author_facet |
Hyun Sik Na Ji Ye Kwon Seon-Yeong Lee Seung Hoon Lee A Ram Lee Jin Seok Woo KyungAh Jung Keun-Hyung Cho Jeong-Won Choi Dong Hwan Lee Hong-Ki Min Sung-Hwan Park Seok Jung Kim Mi-La Cho |
author_sort |
Hyun Sik Na |
title |
Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway |
title_short |
Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway |
title_full |
Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway |
title_fullStr |
Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway |
title_full_unstemmed |
Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway |
title_sort |
metformin attenuates monosodium-iodoacetate-induced osteoarthritis via regulation of pain mediators and the autophagy–lysosomal pathway |
publisher |
MDPI AG |
series |
Cells |
issn |
2073-4409 |
publishDate |
2021-03-01 |
description |
Osteoarthritis (OA) is the most common degenerative arthritis associated with pain and cartilage destruction in the elderly; it is known to be involved in inflammation as well. A drug called celecoxib is commonly used in patients with osteoarthritis to control pain. Metformin is used to treat type 2 diabetes but also exhibits regulation of the autophagy pathway. The purpose of this study is to investigate whether metformin can treat monosodium iodoacetate (MIA)-induced OA in rats. Metformin was administered orally every day to rats with OA. Paw-withdrawal latency and threshold were used to assess pain severity. Cartilage damage and pain mediators in dorsal root ganglia were evaluated by histological analysis and a scoring system. Relative mRNA expression was measured by real-time PCR. Metformin reduced the progression of experimental OA and showed both antinociceptive properties and cartilage protection. The combined administration of metformin and celecoxib controlled cartilage damage more effectively than metformin alone. In chondrocytes from OA patients, metformin reduced catabolic factor gene expression and inflammatory cell death factor expression, increased LC3Ⅱb, p62, and LAMP1 expression, and induced an autophagy–lysosome fusion phenotype. We investigated if metformin treatment reduces cartilage damage and inflammatory cell death of chondrocytes. The results suggest the potential for the therapeutic use of metformin in OA patients based on its ability to suppress pain and protect cartilage. |
topic |
osteoarthritis metformin pain cartilage autophagy combination therapy |
url |
https://www.mdpi.com/2073-4409/10/3/681 |
work_keys_str_mv |
AT hyunsikna metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT jiyekwon metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT seonyeonglee metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT seunghoonlee metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT aramlee metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT jinseokwoo metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT kyungahjung metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT keunhyungcho metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT jeongwonchoi metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT donghwanlee metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT hongkimin metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT sunghwanpark metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT seokjungkim metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway AT milacho metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway |
_version_ |
1724212505436225536 |